| 94304-3 |
OxyCODONE & metabolites panel |
- |
Urine |
Pt |
- |
Confirm |
|
ACTIVE |
OxyCODONE and metabolites panel - Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
94304-3 |
|
Confirm |
|
|
Order |
|
|
|
0 |
OxyCODONE+metabolites Pnl Ur Cfm |
|
|
|
|
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Lortab; Metabolite; Metb; OxyCODONE+metabolites Pnl; OxyContin; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Percocet; Percodan; Pnl; Point in time; PotentialForAbuse; Random; UA; UR; Urn; Vicodin |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 94305-0 |
OxyMORphone & Noroxymorphone panel |
- |
Urine |
Pt |
- |
Confirm |
|
ACTIVE |
OxyMORphone and Noroxymorphone panel - Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
94305-0 |
|
Confirm |
|
|
Order |
|
|
|
0 |
OxyMORphone+Noroxymorph Pnl Ur Cfm |
|
|
|
|
|
14-Hydroxydihydromorphinone; Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Numorphan; Numorphone; Opana; Oxycodone metabolite; OxyMORphone+Noroxymorph Pnl; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; PotentialForAbuse; Random; UA; UR; Urn |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 94306-8 |
SARS coronavirus 2 RNA panel |
- |
XXX |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
94306-8 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
SARS-CoV-2 RNA Pnl Spec NAA+probe |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; Pan; PANEL.MICROBIOLOGY; Panl; PCR; PH; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; Random; Ribonucleic acid; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 RNA Pnl; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
Panel |
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 94307-6 |
SARS coronavirus 2 N gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar.CDC primer-probe set N1 |
|
ACTIVE |
SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94307-6 |
|
Probe.amp.tar.CDC primer-probe set N1 |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 N gene Spec Ql NAA N1 |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N1; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 N gene; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 94308-4 |
SARS coronavirus 2 N gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar.CDC primer-probe set N2 |
|
ACTIVE |
SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94308-4 |
|
Probe.amp.tar.CDC primer-probe set N2 |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 N gene Spec Ql NAA N2 |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N2; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 N gene; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 94309-2 |
SARS coronavirus 2 RNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94309-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 RNA Spec Ql NAA+probe |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.73 |
2.68 |
|
|
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 9431-8 |
Isobutanol |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Isobutanol [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
9431-8 |
|
|
|
|
Both |
|
|
|
0 |
Isobutanol Bld-mCnc |
|
|
|
Y |
|
Blood; DRUG/TOXICOLOGY; Drugs; Isobutyl alcohol; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0i |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 94310-0 |
SARS-related coronavirus N gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar.CDC primer-probe set N3 |
|
ACTIVE |
SARS-related coronavirus N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94310-0 |
|
Probe.amp.tar.CDC primer-probe set N3 |
|
|
Both |
|
|
|
0 |
SARS-related CoV N Spec Ql NAA N3 |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N3; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARSr-CoV; SARS-related CoV N; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.7 |
2.68 |
|
|
|
|
|
|
|
|
|
|
Release 2.70: COMPONENT: Updated from "SARS-like" to "SARS-related" based review and approval from CDC and the original term request for their "N3" target.; METHOD_TYP: Updated Method clarify that this test uses the CDC N3 primer-probe set and to align with the existing codes for CDC's N1 and N2 targets.; |
0 |
| 94311-8 |
SARS coronavirus 2 N gene |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar.CDC primer-probe set N1 |
|
ACTIVE |
SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 |
|
MIN |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
94311-8 |
|
Probe.amp.tar.CDC primer-probe set N1 |
|
|
Observation |
|
|
|
0 |
SARS-CoV-2 N gene Ct Spec Qn NAA N1 |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N1; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; PH; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QNT; Quan; Quant; Quantitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 N gene; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
{Ct_value} |
|
|
|
0 |
| 94312-6 |
SARS coronavirus 2 N gene |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar.CDC primer-probe set N2 |
|
ACTIVE |
SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 |
|
MIN |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
94312-6 |
|
Probe.amp.tar.CDC primer-probe set N2 |
|
|
Observation |
|
|
|
0 |
SARS-CoV-2 N gene Ct Spec Qn NAA N2 |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N2; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; PH; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QNT; Quan; Quant; Quantitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 N gene; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
{Ct_value} |
|
|
|
0 |
| 94313-4 |
SARS-related coronavirus N gene |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar.CDC primer-probe set N3 |
|
ACTIVE |
SARS-related coronavirus N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 |
|
NAM |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
94313-4 |
|
Probe.amp.tar.CDC primer-probe set N3 |
|
|
Observation |
|
|
|
0 |
SARS-related CoV N Ct Spec Qn NAA N3 |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Centers for Disease Control and Prevention; Corona virus; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA N3; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; PH; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QNT; Quan; Quant; Quantitative; Random; SARSr-CoV; SARS-related CoV N; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.7 |
2.68 |
|
|
|
|
|
|
|
{Ct_value} |
|
|
Release 2.70: COMPONENT: Updated from "SARS-like" to "SARS-related" based review and approval from CDC and the original term request for their "N3" target.; METHOD_TYP: Updated Method clarify that this test uses the CDC N3 primer-probe set and to align with the existing codes for CDC's N1 and N2 targets.; |
0 |
| 94314-2 |
SARS coronavirus 2 RdRp gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94314-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 RdRp Spec Ql NAA+probe |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 RdRp; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 94315-9 |
SARS-related coronavirus E gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
SARS-related coronavirus E gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94315-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
SARS-rel CoV E gene Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARSr-CoV; SARS-rel CoV E gene; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94316-7 |
SARS coronavirus 2 N gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94316-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
SARS-CoV-2 N gene Spec Ql NAA+probe |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; PH; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; QL; Qual; Qualitative; Random; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 N gene; Screen; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus |
2.69 |
2.68 |
|
|
81959-9 |
|
|
|
|
|
|
|
|
0 |
| 94318-3 |
Plan of care note |
Find |
{Setting} |
Pt |
Doc |
Medical aid in dying |
|
ACTIVE |
Medical Aid in Dying Plan of care note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94318-3 |
|
Medical aid in dying |
|
|
Both |
|
|
|
0 |
MAiD Plan of care note |
|
|
|
|
|
Assisted suicide; Care plan; Death with dignity; DOC.ONT; Document; Encounter; End of life option; Evaluation and management; Evaluation and management note; Finding; Findings; MAiD; Medical assistance in dying; Medical assisted death; notes; Physician-assisted death; Point in time; Random; Treatment plan; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94319-1 |
Consultation note |
Find |
{Setting} |
Pt |
Doc |
Medical aid in dying |
|
ACTIVE |
Medical Aid in Dying Consult note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94319-1 |
|
Medical aid in dying |
|
|
Both |
|
|
|
0 |
MAiD Consult note |
|
|
|
|
|
Assisted suicide; Consult note; Death with dignity; DOC.ONT; Document; Encounter; End of life option; Evaluation and management; Evaluation and management note; Finding; Findings; MAiD; Medical assistance in dying; Medical assisted death; notes; Physician-assisted death; Point in time; Random; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9432-6 |
Isobutyl acetate |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Isobutyl acetate [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
9432-6 |
|
|
|
|
Both |
|
|
|
0 |
Isobutyl Acetate Spec-mCnc |
|
|
|
Y |
|
Acetic acid; DRUG/TOXICOLOGY; Drugs; Ethanoate; Ethanoic acid; Iso-butyl acetate; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.7 |
1.0i |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 94320-9 |
Procedure note |
Find |
{Setting} |
Pt |
Doc |
Medical aid in dying |
|
ACTIVE |
Medical Aid in Dying procedure note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94320-9 |
|
Medical aid in dying |
|
|
Both |
|
|
|
0 |
MAiD Procedure note |
|
|
|
|
|
Assisted suicide; Death with dignity; DOC.ONT; Document; Encounter; End of life option; Evaluation and management; Evaluation and management note; Finding; Findings; MAiD; Medical assistance in dying; Medical assisted death; notes; Physician-assisted death; Point in time; Random; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94321-7 |
Note |
Find |
{Setting} |
Pt |
Doc |
Medical aid in dying.team |
|
ACTIVE |
Medical Aid in Dying Team Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94321-7 |
|
Medical aid in dying.team |
|
|
Both |
|
|
|
0 |
MAiD Team Note |
|
|
|
|
|
Assisted suicide; Death with dignity; DOC.ONT; Document; Encounter; End of life option; Evaluation and management; Evaluation and management note; Finding; Findings; MAiD; MAiD Team; Medical assistance in dying; Medical assisted death; notes; Physician-assisted death; Point in time; Random; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94322-5 |
Note |
Find |
Telephone encounter |
Pt |
Doc |
Medical aid in dying |
|
ACTIVE |
Medical Aid in Dying Telephone encounter Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94322-5 |
|
Medical aid in dying |
|
|
Observation |
|
|
|
0 |
MAiD Phone Note |
|
|
|
|
|
Assisted suicide; Death with dignity; DOC.ONT; Document; Encounter; End of life option; Evaluation and management; Evaluation and management note; Finding; Findings; MAiD; Medical assistance in dying; Medical assisted death; notes; Physician-assisted death; Point in time; Random; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94323-3 |
Conference note |
Find |
{Setting} |
Pt |
Doc |
Wound, ostomy, and continence care.team |
|
ACTIVE |
Wound, Ostomy, and Continence Care Team Conference note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94323-3 |
|
Wound, ostomy, and continence care.team |
|
|
Both |
|
|
|
0 |
WOC Team Conf note |
|
|
|
|
|
Conf note; Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note; WOC; WOC Team |
2.78 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94324-1 |
Care management note |
Find |
{Setting} |
Pt |
Doc |
Orthopaedic surgery |
|
ACTIVE |
Orthopaedic surgery Care management note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94324-1 |
|
Orthopaedic surgery |
|
|
Both |
|
|
|
0 |
Orthopaedic surgery Care management note |
|
|
|
|
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Orthopedic; Orthopedic surgery; Point in time; Random; Surg; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94327-4 |
PhenX - human papillomavirus vaccine use protocol 100802 |
- |
^Patient |
Pt |
- |
PhenX |
|
ACTIVE |
PhenX - human papillomavirus vaccine use protocol 100802 |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.PHENX |
|
94327-4 |
|
PhenX |
|
|
Order |
|
|
|
0 |
PhenX - HPV vaccine use protocol |
|
|
|
|
|
Pan; Panel; PANEL.PHENX; Panl; PhenX - HPV vaccine use protocol; Pnl; Point in time; Random |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 94328-2 |
Patient health questionnaire 8 item total score |
Score |
^Patient |
Pt |
Qn |
Reported.PHQ |
|
ACTIVE |
Patient Health Questionnaire 8 item (PHQ-8) total score [Reported] |
|
ADD |
DefinitionDescription |
|
|
score |
|
|
|
|
|
|
SURVEY.PHQ |
|
94328-2 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
|
|
|
|
Patient Health Questionnaire; PHQ; PHQ-8; PHQ-8 total score; Point in time; QNT; Quan; Quant; Quantitative; Random; Scale; Survey; SURVEY.PHQ; Tot; Totl |
2.68 |
2.68 |
|
|
|
|
|
|
|
{score} |
|
|
|
0 |
| 94329-0 |
Patient Health Questionnaire 8 item |
- |
^Patient |
Pt |
- |
Reported.PHQ |
|
ACTIVE |
Patient Health Questionnaire 8 item (PHQ-8) [Reported] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.PHQ |
|
94329-0 |
|
Reported.PHQ |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
Pan; Panel; PANEL.SURVEY.PHQ; Panl; Patient Health Questionnaire; PHQ; PHQ-8; Pnl; Point in time; Random; Survey; SURVEY.PHQ |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
